High Effectiveness of CoronaVac Vaccine Against Severe COVID-19 in Adult and Elderly Population in Indonesia

Didan Ariadapa Rahadi; Elfira Yusri; Syandrez Prima Putra; Cimi Ilmiawati

doi:10.2991/978-94-6463-431-0_6

<Previous Article In Volume

Next Article In Volume>

High Effectiveness of CoronaVac Vaccine Against Severe COVID-19 in Adult and Elderly Population in Indonesia

Authors

Didan Ariadapa Rahadi¹^{, *}, Elfira Yusri², Syandrez Prima Putra³^{, 4}, Cimi Ilmiawati⁵^{, 6}

¹Undergraduate Program of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

²Department of Clinical Pathology, Undergraduate Program of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

³Department of Microbiology, Undergraduate Program of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

⁴Center for Diagnostic and Research On Infectious Disease (PDRPI), Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

⁵Doctoral Program of Public Health, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

⁶Department of Pharmacology, Undergraduate Program of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia

^*Corresponding author.

Corresponding Author

Didan Ariadapa Rahadi

Available Online 30 May 2024.

DOI: 10.2991/978-94-6463-431-0_6 How to use a DOI?
Keywords: Effectiveness; CoronaVac; Severe; Adult; Elderly
Abstract: CoronaVac was the first COVID-19 vaccine used in Indonesia. Phase three clinical trial studies showed that the efficacy of CoronaVac in preventing SARS-CoV-2 infection ranged from 50.7-84.4%. The effectiveness of the COVID-19 vaccine in the adult group relatively was better than the elderly group, this study aimed to assess the real-world effectiveness of CoronaVac in adult and elderly age groups in Indonesia.This study was a single-center cohort retrospective study involving COVID-19 patients aged ≥18 years who were admitted to a secondary teaching hospital from June 1 to August 31, 2021. We analyzed two age group models based on WHO, adult (18-59 years) and elderly (≥60 years) models. We used binary logistic regression models to assess the effect of CoronaVac vaccination on severe COVID-19 with sex and comorbidity confounding models. A total of 706 patients were included in this study with 35.4% and 16.5% of patients vaccinated in the adult and elderly groups, respectively. The CoronaVac vaccine has high efficacy in preventing severe COVID-19 in the adult and elderly populations, 93.2% (95% CI: 47.4-99.1%) and 94.8% (95% CI: 55.4-99.4%), respectively. CoronaVac vaccine has a relatively high effectiveness in protecting against severe COVID-19 in both adult and elderly populations.
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume

Next Article In Volume>

Volume Title: Proceedings of selected papers of International Conference on Health, Science, and Environment (ICHSE 2023)
Series: Advances in Biological Sciences Research
Publication Date: 30 May 2024
ISBN: 978-94-6463-431-0
ISSN: 2468-5747
DOI: 10.2991/978-94-6463-431-0_6 How to use a DOI?
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

ris enw bib

TY  - CONF
AU  - Didan Ariadapa Rahadi
AU  - Elfira Yusri
AU  - Syandrez Prima Putra
AU  - Cimi Ilmiawati
PY  - 2024
DA  - 2024/05/30
TI  - High Effectiveness of CoronaVac Vaccine Against Severe COVID-19 in Adult and Elderly Population in Indonesia
BT  - Proceedings of selected papers of International Conference on Health, Science, and Environment (ICHSE 2023)
PB  - Atlantis Press
SP  - 46
EP  - 54
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6463-431-0_6
DO  - 10.2991/978-94-6463-431-0_6
ID  - Rahadi2024
ER  -

download .riscopy to clipboard